The purpose of the present study was to evaluate the effects of subgingival delivery of 1.2% Rosuvastatin (RSV) gel as an adjunct to scaling and root planing in chronic periodontitis (CP) with Type 2 diabetes mellitus patients.
Background: The purpose of this double-masked, randomized, controlled clinical trial was to evaluate the effects of subgingival delivery of 1.2% Rosuvastatin gel as an adjunct to scaling and root planing (SRP) on clinical and radiographic parameters and compare this method with SRP plus placebo gel alone in chronic periodontitis (CP) with type 2 DM patients. Methods: Eighty CP patients with type 2 DM are included in this study. They were divided into two groups: 1) SRP + 1.2% Rosuvastatin gel (RSV group); 2) SRP + Placebo gel (Placebo group). At baseline, 3, 6 and 9 months after treatment, clinical measurements, including plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), clinical attachment level (CAL) and radiographic parameters intrabony defect depth (IBD), percentage change in radiographic defect depth reduction (DDR%) were assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
SRP followed by 1.2% Rosuvastatin placement into intrabony defect
SRP followed by placebo gel placement into intrabony defect
Government Dental College and Research Institute
Bangalore, Karnataka, India
Defect depth reduction (%)
Assessed in percentage
Time frame: Change from baseline to 9 months
probing depth (mm)
measured in mm
Time frame: Change from baseline to 9 months
clinical attachment level (mm)
measured in mm
Time frame: Change from baseline to 9 months
modified sulcus bleeding index
scale from 0-3
Time frame: Change from baseline to 9 months
plaque index
scale from 0-3
Time frame: Change from baseline to 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.